From Pulse 2.0 · Amit Chowdhry · · 1m
ADC Therapeutics Raises $86.6 Million
ADC Therapeutics secures $86.6 million to extend cash runway to 2029.
In brief
ADC Therapeutics secures $86.6 million to extend cash runway to 2029. ADC Therapeutics raised $86.6 million to extend cash runway into 2029. Originally reported by Pulse 2.0.
Financial Restructuring Announced
ADC Therapeutics announced a comprehensive financial restructuring including an $86.6 million private placement and loan refinancing.
Private Placement Details
The $86.6 million private investment includes 12.9 million common shares priced at $1.42 per share.
Pre-Funded Warrants
ADC Therapeutics sells pre-funded warrants to purchase 48.1 million common shares at $1.32 per warrant.
PIPE Closing Date
The PIPE is expected to close on October 22, 2026, subject to customary closing conditions.
ZYNLONTA Development
ADC Therapeutics plans to use funds for ZYNLONTA Phase 3 trials in diffuse large B-cell lymphoma and marginal zone lymphoma.
Healthcare Royalty Amendment
Healthcare Royalty amended agreement eliminates $150 million payment and reduces third-party indebtedness to $50 million.
The main idea
ADC Therapeutics raised $86.6 million to extend cash runway into 2029.
